Amgen Aranesp, Anakinra Could Lead 2001 Biologics Approvals
Amgen anticipates approval for two new biologics in 2001, the red blood cell stimulating factor Aranesp and the interleukin-1 receptor antagonist anakinra.
Amgen anticipates approval for two new biologics in 2001, the red blood cell stimulating factor Aranesp and the interleukin-1 receptor antagonist anakinra.